S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy

Revolution Medicines (RVMD) Stock Price, News & Analysis

$29.17
0.00 (0.00%)
(As of 02/21/2024 ET)
Today's Range
$28.43
$29.23
50-Day Range
$25.69
$30.57
52-Week Range
$15.44
$35.60
Volume
809,267 shs
Average Volume
1.09 million shs
Market Capitalization
$3.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.82

Revolution Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
26.2% Upside
$36.82 Price Target
Short Interest
Bearish
15.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.65mentions of Revolution Medicines in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$1.60 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.47) to ($3.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.77 out of 5 stars

Medical Sector

233rd out of 932 stocks

Biological Products, Except Diagnostic Industry

33rd out of 160 stocks


RVMD stock logo

About Revolution Medicines Stock (NASDAQ:RVMD)

Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Stock Price History

RVMD Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
RVMD Mar 2024 33.000 call
RVMD Mar 2024 22.500 put
RVMD Jun 2024 12.500 put
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
RVMD Sep 2024 19.000 put
Revolution Medicines Inc (RVMD)
Revolution Medicines Is Hard To Understand
Revolution Medicines Inc Insider Sells Shares
Cancer Player Revolution Medicines Gets Bullish Rating: Here's Details
See More Headlines
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
2/22/2024
Next Earnings (Confirmed)
2/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
338
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.82
High Stock Price Target
$47.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+26.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$-248,710,000.00
Net Margins
-1,003.36%
Pretax Margin
-1,281.44%

Debt

Sales & Book Value

Annual Sales
$35.38 million
Book Value
$7.72 per share

Miscellaneous

Free Float
100,252,000
Market Cap
$3.20 billion
Optionable
Optionable
Beta
1.54
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives















RVMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price target for 2024?

11 Wall Street analysts have issued 1-year price objectives for Revolution Medicines' shares. Their RVMD share price targets range from $23.00 to $47.00. On average, they anticipate the company's stock price to reach $36.82 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2024?

Revolution Medicines' stock was trading at $28.68 at the beginning of 2024. Since then, RVMD stock has increased by 1.7% and is now trading at $29.17.
View the best growth stocks for 2024 here
.

Are investors shorting Revolution Medicines?

Revolution Medicines saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 16,950,000 shares, an increase of 6.7% from the January 15th total of 15,880,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the short-interest ratio is currently 11.9 days.
View Revolution Medicines' Short Interest
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our RVMD earnings forecast
.

How can I listen to Revolution Medicines' earnings call?

Revolution Medicines will be holding an earnings conference call on Monday, February 26th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.02. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 38.92%. During the same quarter in the previous year, the business earned ($0.87) earnings per share.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

(RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (13.36%), Nextech Invest Ltd. (5.75%), BVF Inc. IL (5.46%), Bellevue Group AG (4.65%), Price T Rowe Associates Inc. MD (4.23%) and Price T Rowe Associates Inc. MD (4.23%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVMD) was last updated on 2/22/2024 by MarketBeat.com Staff